Pricing Term Insurance in the Presence of a Family History of Breast or Ovarian Cancer
From MaRDI portal
Publication:5718092
Recommendations
- The genetics of breast and ovarian cancer. II: A model of critical illness insurance
- The Genetics of Breast and Ovarian Cancer III: A new model of family history with insurance applications
- The genetics of breast and ovarian cancer. V: Application to income protection insurance
- The genetics of breast and ovarian cancer. I: A model of family history
- Use of a Markov Model to Estimate Long-Term Insured Lives’ Mortality Risk Associated With BRCA1 and BRCA2 Gene Mutations
Cites work
Cited in
(11)- The Genetics of Breast and Ovarian Cancer III: A new model of family history with insurance applications
- Why Do Females Live Longer Than Males?
- The impact of known breast cancer polygenes on critical illness insurance
- Genetics, insurance and hypertrophic cardiomyopathy
- Use of a Markov Model to Estimate Long-Term Insured Lives’ Mortality Risk Associated With BRCA1 and BRCA2 Gene Mutations
- The genetics of breast and ovarian cancer. IV: A model of breast cancer progression
- The genetics of breast and ovarian cancer. V: Application to income protection insurance
- The genetics of breast and ovarian cancer. II: A model of critical illness insurance
- Waiting period from diagnosis for mortgage insurance issued to cancer survivors
- Sampling Distributions of Critical Illness Insurance Premium Rates: Breast and Ovarian Cancer
- Genetics and Insurance: What have we Learned So Far?
This page was built for publication: Pricing Term Insurance in the Presence of a Family History of Breast or Ovarian Cancer
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q5718092)